BMO Capital Downgrades Bristol-Myers Squibb to Market Perform, Announces $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan Seigerman has downgraded Bristol-Myers Squibb (NYSE:BMY) from Outperform to Market Perform and set a price target of $60.
October 27, 2023 | 10:40 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Bristol-Myers Squibb has been downgraded by BMO Capital from Outperform to Market Perform with a price target of $60.
The downgrade from Outperform to Market Perform by BMO Capital indicates a less optimistic outlook for Bristol-Myers Squibb. This could potentially lead to a decrease in the stock's price in the short term. The $60 price target also provides a benchmark for investors, which could influence trading decisions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100